Mitigation of Breast Cancer Cells' Invasiveness Via Down Regulation of ETV7, Hippo, and PI3K/mTOR Pathways by Vitamin D3 Gold-Nanoparticles

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 May 25

PMID 38791386

Authors

Moumita Roy

Fazle Hussain

Affiliations

Soon will be listed here.

Abstract

Metastasis in breast cancer is the major cause of death in females (about 30%). Based on our earlier observation that Vitamin D3 downregulates mTOR, we hypothesized that Vitamin D3 conjugated to gold nanoparticles (VD3-GNPs) reduces breast cancer aggressiveness by downregulating the key cancer controller PI3K/AKT/mTOR. Western blots, migration/invasion assays, and other cell-based, biophysical, and bioinformatics studies are used to study breast cancer cell aggressiveness and nanoparticle characterization. Our VD3-GNP treatment of breast cancer cells (MCF-7 and MDA-MB-231) significantly reduces the aggressiveness (cancer cell migration and invasion rates > 45%) via the simultaneous downregulation of ETV7 and the Hippo pathway. Consistent with our hypothesis, we, indeed, found a downregulation of the PI3K/AKT/mTOR pathway. It is surprising that the extremely low dose of VD3 in the nano formulation (three orders of magnitude lower than in earlier studies) is quite effective in the alteration of cancer invasiveness and cell signaling pathways. Clearly, VD3-GNPs are a viable candidate for non-toxic, low-cost treatment for reducing breast cancer aggressiveness.

References

Veeresh P, Basavaraju C, Dallavalasa S, Anantharaju P, Natraj S, Sukocheva O . Vitamin D3 Inhibits the Viability of Breast Cancer Cells In Vitro and Ehrlich Ascites Carcinomas in Mice by Promoting Apoptosis and Cell Cycle Arrest and by Impeding Tumor Angiogenesis. Cancers (Basel). 2023; 15(19). PMC: 10571758. DOI: 10.3390/cancers15194833. View

Clogston J, Patri A . Zeta potential measurement. Methods Mol Biol. 2010; 697:63-70. DOI: 10.1007/978-1-60327-198-1_6. View

Sengupta S, Peterson T, Sabatini D . Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010; 40(2):310-22. PMC: 2993060. DOI: 10.1016/j.molcel.2010.09.026. View

Gombart A, Pierre A, Maggini S . A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection. Nutrients. 2020; 12(1). PMC: 7019735. DOI: 10.3390/nu12010236. View

Zhao C, Zeng C, Ye S, Dai X, He Q, Yang B . Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer. Acta Pharm Sin B. 2020; 10(6):947-960. PMC: 7332664. DOI: 10.1016/j.apsb.2019.12.010. View

Blasiak J, Pawlowska E, Chojnacki J, Szczepanska J, Fila M, Chojnacki C . Vitamin D in Triple-Negative and BRCA1-Deficient Breast Cancer-Implications for Pathogenesis and Therapy. Int J Mol Sci. 2020; 21(10). PMC: 7279503. DOI: 10.3390/ijms21103670. View

Kevadiya B, Ottemann B, Thomas M, Mukadam I, Nigam S, McMillan J . Neurotheranostics as personalized medicines. Adv Drug Deliv Rev. 2018; 148:252-289. PMC: 6486471. DOI: 10.1016/j.addr.2018.10.011. View

Marcinowska-Suchowierska E, Kupisz-Urbanska M, Lukaszkiewicz J, Pludowski P, Jones G . Vitamin D Toxicity-A Clinical Perspective. Front Endocrinol (Lausanne). 2018; 9:550. PMC: 6158375. DOI: 10.3389/fendo.2018.00550. View

Yu F, Zhao B, Guan K . Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015; 163(4):811-28. PMC: 4638384. DOI: 10.1016/j.cell.2015.10.044. View

10.

Li H, Zhang Y, Zheng S . Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer. Biomed Res Int. 2021; 2021:8530186. PMC: 8678556. DOI: 10.1155/2021/8530186. View

11.

Harwood F, Geltink R, OHara B, Cardone M, Janke L, Finkelstein D . ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer. Sci Adv. 2018; 4(9):eaar3938. PMC: 6156121. DOI: 10.1126/sciadv.aar3938. View

12.

Nah H, Lee D, Heo M, Lee J, Lee S, Heo D . Vitamin D-conjugated gold nanoparticles as functional carriers to enhancing osteogenic differentiation. Sci Technol Adv Mater. 2019; 20(1):826-836. PMC: 6713151. DOI: 10.1080/14686996.2019.1644193. View

13.

Alayev A, Holz M . mTOR signaling for biological control and cancer. J Cell Physiol. 2013; 228(8):1658-64. PMC: 4491917. DOI: 10.1002/jcp.24351. View

14.

Stoll F, Akladios C, Mathelin C . [Vitamin D and breast cancer: is there a link?]. Gynecol Obstet Fertil. 2013; 41(4):242-50. DOI: 10.1016/j.gyobfe.2013.02.002. View

15.

Akinc A, Battaglia G . Exploiting endocytosis for nanomedicines. Cold Spring Harb Perspect Biol. 2013; 5(11):a016980. PMC: 3809578. DOI: 10.1101/cshperspect.a016980. View

16.

Kudryashova T, Goncharov D, Pena A, Kelly N, Vanderpool R, Baust J . HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension. Am J Respir Crit Care Med. 2016; 194(7):866-877. PMC: 5074651. DOI: 10.1164/rccm.201510-2003OC. View

17.

Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X . Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019; 18(1):26. PMC: 6379961. DOI: 10.1186/s12943-019-0954-x. View

18.

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

19.

Basu S, Totty N, Irwin M, Sudol M, Downward J . Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell. 2003; 11(1):11-23. DOI: 10.1016/s1097-2765(02)00776-1. View

20.

Eiger D, Agostinetto E, Saude-Conde R, de Azambuja E . The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers (Basel). 2021; 13(5). PMC: 7957750. DOI: 10.3390/cancers13051015. View